Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- Chandigarh: 62% industrial units plan to cut manpower
- Govt likely to impose check on China imports in Budget FY24
- Airport lounge access through cards getting tougher: Factors you must know to avoid last-minute shock
- XLRI PGDM (GM) Has Successfully Completed Its Consulting Conclave – FULCRUM – Decoding the Future of Consulting
